
Opinion|Videos|September 4, 2024
Ravulizumab Long-Term Data and Management of NMOSD
Author(s)Michael Levy, MD, PhD
This discussion examines the 138-week data on ravulizumab for NMOSD, focusing on long-term relapse rates, and share practical tips for effective NMOSD management in clinical settings.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- The 138-week data for ravulizumab, the most recently approved neuromyelitis optica spectrum disorder (NMOSD) treatment, was presented at the 2024 American Academy of Neurology Annual Meeting. What do we know about relapses while on ravulizumab in the long term?
- Please share practical tips for management of NMOSD in the clinic.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Clears Roche’s Elecsys pTau181 Test for Ruling Out Alzheimer-Related related Amyloid Pathology
2
Inside the Phase 3 MASCOT Trial: Lundbeck’s Push for the First Disease-Modifying MSA Therapy
3
Phase 2 OPAL Study to Test Muscle-Targeting Therapy Apitegromab in Infants With SMA
4
Decision-Making in De-Escalating Therapy for Multiple Sclerosis
5